Human Pro-Collagen I α1 Standard (人I型前胶原蛋白标准品)
¥280.00
- 分子靶点:COL1A1, Pro-Collagen I α1
- 种属:人 (Human)
- 试剂盒:EK1C01
- 保存:短期4℃保存,长期-20℃保存
- 运输条件:4℃蓝冰运输
在售SKU:70-EK1C01S
文章目录[隐藏]
本产品只包含标准品试剂,如需购买试剂盒请点击下图
-
- EK1C01
- ELISA试剂盒
Human Pro-Collagen I α1 ELISA Kit检测试剂盒(酶联免疫吸附法)
- ¥2,000.00 – ¥3,400.00
商品名 |
Human Pro-Collagen I α1 Standard (人I型前胶原蛋白标准品) |
---|---|
组分 |
重组人Pro-Collagen I α1标准品 |
板式 |
管 |
保存 |
试剂盒未拆开,4℃保存。已拆开,标准品-20℃保存,其它4℃保存。 |
运输条件 |
4℃蓝冰运输 |
COL1A1 分子靶点信息概述
- 分子名:COL1A1, collagen type I alpha 1 chain
- 基因家族:Collagens
- 别名:collagen, type I, alpha 1; OI4
COL1A1 分子靶点综述
I 型胶原蛋白是皮肤、骨骼和肌腱等结缔组织中含量最丰富的结构蛋白。它是一种合成的前胶原分子,其特征为 300 nm 的三重螺旋结构域,两侧是球状的 N 端和 c 端前肽。三螺旋结构域包含 Gly-Xaa-Yaa 三联体,其中 Xaa 和 Yaa 通常分别是脯氨酸和羟脯氨酸。前胶原蛋白 N 和 C 蛋白酶活性去除非螺旋前肽,因此成熟的三螺旋可以自组装成胶原原纤维,为组织提供拉伸强度。
COL1A1, collagen type I alpha 1 chain 分子靶点种属信息
人 Human COL1A1 分子靶点信息
- 分子名:COL1A1, collagen type I alpha 1 chain
- 别称:
- alpha-1 type I collagen
- alpha1(I) procollagen
- CAFYD
- collagen alpha 1 chain type I
- collagen alpha-1(I) chain
- collagen alpha-1(I) chain preproprotein
- collagen of skin, tendon and bone, alpha-1 chain
- collagen type I alpha 1
- collagen, type I, alpha 1
- EDSARTH1
- EDSC
- OI1
- OI2
- OI3
- OI4
- pro-alpha-1 collagen type 1
- type I proalpha 1
- type I procollagen alpha 1 chain
- 基因序列:NCBI_Gene: 1277
- 蛋白序列:UniProtKB: P02452
人 Human COL1A1靶点分子功能(预测)
Enables identical protein binding activity; platelet-derived growth factor binding activity; and protease binding activity. Involved in several processes, including collagen biosynthetic process; collagen fibril organization; and skin morphogenesis. Acts upstream of or within skeletal system development. Located in extracellular space. Part of collagen type I trimer. Colocalizes with collagen-containing extracellular matrix. Implicated in several diseases, including Ehlers-Danlos syndrome arthrochalasia type 1; aggressive periodontitis; bone disease (multiple); cutaneous leishmaniasis; and dentinogenesis imperfecta. Biomarker of several diseases, including alcoholic hepatitis; autoimmune disease (multiple); chronic obstructive pulmonary disease; end stage renal disease; and lupus nephritis.